648906-28-9

Usage

Uses

Used in Organic Synthesis:
1-Bromo-4-(cyclopropanesulfonyl)benzene is used as a building block in organic synthesis for its ability to facilitate the creation of complex organic molecules. Its unique structure allows for a range of reactions that can be harnessed to produce diverse chemical entities.
Used in Pharmaceutical Research and Drug Discovery:
In the pharmaceutical industry, 1-Bromo-4-(cyclopropanesulfonyl)benzene is utilized as a reagent in chemical reactions aimed at discovering and developing potential therapeutic agents. Its properties make it a promising candidate for the synthesis of new drugs with various medicinal applications.
Used in Agrochemical Development:
1-Bromo-4-(cyclopropanesulfonyl)benzene may also find applications in the development of agrochemicals, where its chemical versatility can contribute to the creation of novel compounds for agricultural use, potentially enhancing crop protection and yield.
Used in Materials Science:
Furthermore, 1-Bromo-4-(cyclopropanesulfonyl)benzene has potential uses in materials science, where its unique properties could be employed in the development of new materials with specific characteristics, such as improved stability, reactivity, or other desirable traits for various applications.

Upstream product

• 16181-12-7 (4-bromophenyl)-(3-chloropropyl)sulfane 
• 14633-54-6 cyclopropylphenylsulfide 
• 106-53-6 para-bromobenzenethiol 
• 411229-63-5 1-bromo-4-(cyclopropylsulfanyl)benzene 

Downstream Products

• 1374986-49-8 3-(4-(cyclopropylsulfonyl)phenoxy)-5-((3-methylbut-2-en-1-yl)oxy)-N-(thiazol-2-yl)benzamide 
• 1374986-52-3 3-(4-(cyclopropylsulfonyl)phenoxy)-N-(5-fluorothiazol-2-yl)-5-((3-methylbut-2-en-1-yl)oxy)benzamide 
• 1374986-60-3 3-(4-(cyclopropylsulfonyl)phenoxy)-N-(4-(4-fluorophenyl)thiazol-2-yl)-5-((3-methylbut-2-en-1-yl)oxy)benzamide 
• 1374986-61-4 N-(4-(tert-butyl)thiazol-2-yl)-3-(4-(cyclopropylsulfonyl)phenoxy)-5-((3-methylbut-2-en-1-yl)oxy)benzamide 
• 1374986-62-5 3-(4-(cyclopropylsulfonyl)phenoxy)-5-((3-methylbut-2-en-1-yl)oxy)-N-(4-oxo-4,5-dihydrothiazol-2-yl)benzamide 
• 1374986-63-6 3-(4-(cyclopropylsulfonyl)phenoxy)-N-(1,5-dimethyl-1H-pyrazol-3-yl)-5-((3-methylbut-2-en-1-yl)oxy)benzamide 
• 1374986-64-7 3-(4-(cyclopropylsulfonyl)phenoxy)-5-((3-methylbut-2-en-1-yl)oxy)-N-(5-methylpyrazin-2-yl)benzamide 
• 1374986-65-8 3-(4-(cyclopropylsulfonyl)phenoxy)-N-(imidazo[1,2-a]pyrazin-8-yl)-5-((3-methylbut-2-en-1-yl)oxy)benzamide 
• 1374986-51-2 C₂₁H₂₂O₆S 
• 648906-27-8 2-[4-(cyclopropanesulfonyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 

Relevant academic research and scientific papers

NOVEL APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS

The present invention relates to inhibitors of apoptosis signal-regulating kinase 1 ("ASK1"), a process for synthesis of the compounds of the present invention, composition comprising the compounds and use of the compounds for inhibition of ASK1.

PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF

Disclosed herein is a compound of Formula (AIII) or (III), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators

A series of benzamide derivatives were assembled by using the privileged-fragment-merging (PFM) strategy and their SAR studies as glucokinase activators were described. Compounds 5 and 16b were identified having a suitable balance of potency and activation profile. They showed EC50 values of 28.3 and 44.8 nM, and activation folds of 2.4 and 2.2, respectively. However, both compounds displayed a minor reduction in plasma glucose levels on imprinting control region (ICR) mice. Unfavorable pharmacokinetic profiles (PK) were also observed on these two compounds.

SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP

The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.